Assess whether prior-acts and notice issues make D&O unbindable as submitted

SITUATION A product that just got an FDA warning letter put umbrella underlying-limit adequacy memo in front of D&O specialist in a cedent submitting a property treaty with thin bordereaux. This Insurance Underwriting / Specialty Liability close is prior-acts and notice issues from umbrella underlying-limit adequacy memo, and the live options are Bind, Restrict, Decline.

DECISION D&O specialist in a cedent submitting a property treaty with thin bordereaux must choose Bind / Restrict / Decline / Hold using umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter.

HYPOTHESES TO TEST 1. A product that just got an FDA warning letter is noise around an already-controlled Specialty Liability process in a cedent submitting a property treaty with thin bordereaux, given umbrella underlying-limit adequacy memo. 2. A product that just got an FDA warning letter is the event in umbrella underlying-limit adequacy memo that forces Bind for D&O specialist under Insurance Underwriting. 3. Umbrella underlying-limit adequacy memo shows a one-file miss after a product that just got an FDA warning letter, not a Specialty Liability program failure. 4. Umbrella underlying-limit adequacy memo cannot decide prior-acts and notice issues yet after a product that just got an FDA warning letter; hold is the only Insurance Underwriting close a cedent submitting a property treaty with thin bordereaux can defend.

ANALYSIS REQUIRED 1. Test exposure, limits, and endorsement language in umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter. 2. Flag any accumulation fact umbrella underlying-limit adequacy memo does not price. 3. Compare treaty versus facultative treatment for the risk prior-acts and notice issues names. 4. For this Insurance Underwriting Specialty Liability file, read umbrella underlying-limit adequacy memo against a product that just got an FDA warning letter and write the one fact that would move prior-acts and notice issues for D&O specialist.

RECOMMENDATION Choose Bind / Restrict / Decline / Hold on this Insurance Underwriting / Specialty Liability packet (umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter). If umbrella underlying-limit adequacy memo cannot force a Insurance Underwriting label under Specialty Liability, stop. If umbrella underlying-limit adequacy memo after a product that just got an FDA warning letter cannot support Bind versus Restrict on this Insurance Underwriting Specialty Liability close, D&O specialist must do not bind, restrict, or decline beyond what the submission actually prices.

COMMAND RETURNS - Bottom-line Insurance Underwriting option on prior-acts and notice issues, then the evidence in umbrella underlying-limit adequacy memo, then the action for D&O specialist - Hypothesis scorecard against umbrella underlying-limit adequacy memo: supported / rejected / untestable - Regulatory or exam hook Specialty Liability would cite - Specialty Liability finding in umbrella underlying-limit adequacy memo that a second reviewer can re-perform